Good Evening Market Enthusiast,
Some stories don't whisper. They scream.
Tomorrow’s drop centers on a tiny float biotech with a greenlit cancer drug about to ship — and that's just chapter one.
This isn’t one of those “someday” hopefuls. It's FDA-approved. Commercial-ready. Shelf-stable. Nationwide distribution secured. A full team already
targeting prescribers.
The float? Minuscule. The upside? Let’s just say some targets sit 2x–3x above current levels — and that’s before revenue hits.
Oh — and they still own most of their oncology spin-off, which by itself is valued several times higher than the parent company’s market cap. Hidden equity, hiding in plain sight.
There’s a second therapy tracking toward a fast-tracked FDA decision next year,
and a third eyeing an unmet everyday need with massive demand.
This one checks every retail ignition box:
✅ Real product
✅ Near-term catalysts
✅ Clean cap table
✅ Insider skin in the game
✅ And a spin-off twist that could unlock serious value
Tomorrow morning, we walk you through it all. Full breakdown. Full receipts.
Set your alarms. And don’t be the one asking how you missed it.
To
your success,
Max Masters
Co-founder, Market Tips Newsletter
